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Topically Applied Flightless I Neutralizing Antibodies
Improve Healing of Blistered Skin in a Murine Model
of Epidermolysis Bullosa Acquisita
Zlatko Kopecki1, Nadira Ruzehaji1, Christopher Turner1, Hioraki Iwata2, Ralf J. Ludwig2, Detlef Zillikens2,
Dedee F. Murrell3 and Allison J. Cowin1,4,5
Epidermolysis bullosa (EB) is a chronic inheritable disease that leads to severe blistering and fibrosis. Previous
studies have shown that the actin cytoskeletal protein flightless I (Flii) impairs wound healing associated with EB.
Using a mouse model of EB acquisita (EBA), the effect of ‘‘mopping up’’ Flii using Flii-neutralizing antibodies
(FnAbs) before, during, and after blister formation was determined. FnAbs, incorporated into a cream vehicle and
applied topically to the skin, penetrated into the basal epidermis and upper papillary dermis but were not
detected in serum or other organs and did not alter neutrophil or macrophage infiltration into the blistered skin.
Histological assessment of blister severity showed that treatment of early-stage blisters with FnAb cream reduced
their severity and improved their rate of healing. Treatment of established blisters with FnAb cream also improved
healing and restored the skin’s tensile strength toward that of normal skin. Repeated application of FnAbs to EBA
skin before the onset of blistering reduced the severity of skin blistering. Independent of when the FnAbs were
applied, skin barrier function and wound healing were improved and skin fragility was reduced, suggesting that
FnAbs could potentially improve healing of patients with EB.
Journal of Investigative Dermatology (2013) 133, 1008–1016; doi:10.1038/jid.2012.457; published online 6 December 2012
INTRODUCTION
Inheritable epidermolysis bullosa (EB) comprises a group of
30 phenotypically or genotypically distinct disorders charac-
terized by recurrent blistering as a result of structural fragility
of skin and mucous membranes (Uitto, 2009). Chronic wound
healing associated with trauma-induced blistering has a
severely negative effect on the patient’s quality of life.
Impaired healing of blisters often results in infections,
scarring, and development of aggressive squamous cell
carcinoma, which lead to metastasis and mortality early in
life (Bruckner-Tuderman, 2010). Mutations of at least 14 genes
encoding for proteins responsible for the maintenance of the
keratinocyte structural stability or adhesion of keratinocytes to
the underlying dermis give rise to differences in the site
of ultrastructural cleavage between the main EB types. EB
simplex is characterized by intraepidermal blistering;
junctional EB and dystrophic EB are characterized by the
blistering within the lamina lucida and sub-lamina densa,
respectively, whereas Kindler syndrome can present with
multiple cleavage plains (Fine, 2010). Patients can also
develop an acquired form of EB called EB acquisita (EBA),
where autoimmunity against type VII collagen results in
subepidermal blistering and clinical features similar to those
observed in dystrophic EB patients (Ishii et al., 2010).
Recent advances in a number of novel molecular strategies
including ex vivo gene therapy (Mavilio et al., 2006; De Luca
et al., 2009), stem cell transplantation (Tolar et al., 2009;
Tamai et al., 2011), and administration of allogeneic
fibroblasts (Wong et al., 2008; Nagy et al., 2011) or
recombinant protein (Fritsch et al., 2009; Remington et al.,
2009) have offered hope for the development of therapies for
patients with EB; however, many technical and safety
problems are still encountered (Uitto et al., 2010, 2011). In
addition, EBA is highly resistant to immunosuppressive agents,
making current treatment difficult (Ishii et al., 2010).
This identifies the need for safer and effective alternatives for
the treatment modalities of all EB types.
The actin-remodeling protein flightless I (Flii) has an
important role in mediating cellular adhesion, hemidesmo-
some structure, and collagen deposition (Kopecki et al., 2009,
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2011a), with key roles in development, wound healing, and
tissue regeneration (Campbell et al., 2002; Lin et al., 2011;
Waters et al., 2011). Flii L-rich repeat domain also allows for
interaction with numerous proteins (Fong and de Couet, 1999;
Kopecki et al., 2009, 2011b) and regulation of cellular
functions, including migration and proliferation (Cowin
et al., 2007), transcriptional regulation (Archer et al., 2004),
focal adhesion turnover (Kopecki et al., 2011b), toll-like
receptor signaling (Dai et al., 2009), inflammation, cytokine
production (Li et al., 2008), and cell division (Deng et al.,
2007). Although the loss of Flii gene leads to embryonic
lethality in both Drosophila (Campbell et al., 1993) and the
mouse (Campbell et al., 2002), the overexpression of Flii gene
leads to thinner more fragile skin, impaired wound healing,
and increased scarring (Cowin et al., 2007; Kopecki et al.,
2009).
Previous studies have demonstrated the negative role for Flii
in wound healing leading to interrupted skin homeostasis, skin
fragility, diffuse arrangements of ColVII-anchoring fibrils, and
impaired cellular adhesion, migration, and proliferation
(Cowin et al., 2007; Kopecki et al., 2009, 2011b). Having a
unique structure to other members of the gelsolin family
of actin-remodeling proteins, Flii has the ability to transduce
the cell signaling events into cytoskeleton remodeling and
therefore link different signaling pathways with the actin
cytoskeleton. Flii is increased in blisters of EB patients, and
its upregulation correlates with the severity of blistering seen
in mouse models of recessive dystrophic epidermolysis
bullosa and EBA (Kopecki et al., 2011a). We have also
described the increased dermal–epidermal separation and
altered TGF-b1/Smad signaling and collagen-mediated con-
traction and fibrosis associated with increased levels of Flii
gene (Kopecki et al., 2011a). Neutralizing the extracellular
Flii activity via intradermal injection of monoclonal Flii-
neutralizing antibodies (FnAbs) accelerates wound reepi-
thelialization and improves the macroscopic appearance of
early scars in porcine models of wound healing (Jackson et al.,
2012). Here, we investigate the effect of topical FnAb cream
on the healing of blisters in an autoimmune ColVII murine
model of EBA.
RESULTS
Topical application of FnAb cream modulates Flii expression
in the skin
Flii is present in the blistered skin of human patients and mice
models of recessive dystrophic epidermolysis bullosa and
EBA. To determine whether it is also secreted, a suction
model of skin blistering was used. Flii levels were analyzed in
human blister fluid and was found to be present in blister
wound fluid and for the two consecutive days post blister
induction (Figure 1a). Compared with acute wound fluid
control, the level of Flii was significantly elevated in human
blister fluid taken at the time of blister creation, with reduced
levels seen at day 1 and day 2 post blistering (Figure 1a and b).
We have previously injected FnAbs (50mg ml1) intradermally
to murine and porcine wounds (Cowin et al., 2007; Adams
et al., 2009; Jackson et al., 2012). To determine whether
FnAbs could be delivered directly to skin and blisters in a
topical cream preparation, FnAb cream was prepared as
described in the Materials and methods by mixing aqueous
cetomacrogol cream with rabbit polyclonal FnAb (50mg ml1)
and directly applied to the skin. In addition, FnAb was directly
conjugated to DyLight Fluor 488 (50mg ml 1), and this was
also incorporated into aqueous cetomacrogol cream to
confirm the penetration of FnAbs into skin. Both the directly
conjugated FnAb-DyLight and FnAb alone showed similar
penetration into the skin, with localization observed in the
basal epidermis and the upper papillary dermis (Figure 1c–h).
Addition of FnAb to the surface of the skin leads to decreased
expression of Flii in the epidermis (Figure 1e) compared with
control IgG cream (Figure 1f). FnAb, detected using indirect
immunohistochemistry, colocalized with Flii protein and was
found in the epidermis, at the epidermal–dermal junction,
and penetrated into the upper papillary dermis with
evident intracellular colocalization staining of fibroblasts
(Figure 1g and h). The effect of FnAb cream on Flii expression
in the skin was further examined in wild-type mice using
western blotting. A single application of FnAb cream
(50mg ml 1 FnAb) rubbed into the dorsal skin of wild-type
mice resulted in reduced expression of Flii (B60% reduction)
for up to 1 day post treatment (Figure 1i–j). At 2 days post
treatment, Flii levels had returned to baseline (Figure 1j).
Topical application of FnAb cream is localized to the skin
Flii levels were investigated in different organs of wild-type
mice and were compared with the levels of Flii in skin using
western blotting and band densitometry. Flii was detected in
the heart and lymph nodes at levels lower than those observed
in skin; however, levels of Flii in the lung, kidney, and liver
were higher than those observed in the skin (Figure 2a and b).
An ELISA for detection of FnAbs was developed to test
whether the application of FnAb cream to the skin would
have a systemic effect. A single topical application of FnAb
cream (containing 50mg ml 1 FnAb) or dose-matched IgG
control cream was rubbed into the skin of wild-type mice and
to the blistered skin of EBA mice. FnAb levels were detected in
the skin of wild-type mice up to 3 days post treatment
(Figure 2c). FnAb levels were comparable to those observed
in control blistered skin (Figure 2c), but were not detected in
other organs systemically including heart, lung, kidney,
spleen, lymph node, gut, or serum (Figure 2c).
Treatment of early-stage blisters with FnAb cream reduces
their severity in EBA mice
In the immune-mediated model of EB, administration of anti-
ColVII antibodies leads to the disruption of ColVII-anchoring
fibrils, and skin blistering occurs on the backs of the mice from
day 8 post administration. FnAb cream (50mg ml 1 FnAb) was
gently rubbed onto the skin of the EBA mice for three
consecutive days at the start of blister formation (days 8–10).
EBA mice treated with FnAb cream had significantly fewer
blisters and reduced number of lesions compared with EBA
mice treated with control IgG antibody in a cream vehicle
(Figure 3a–c). To determine the effect of FnAb cream on
restoration of skin barrier function following skin blistering,
the transepidermal water loss (TEWL) was measured in EBA
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mice treated with FnAb cream or IgG control cream from day
7 of the experiment. TEWL readings peaked on day 8 in all
mice when the blisters started developing, fluctuated follow-
ing repeated blistering, and returned to basal levels by day 16
of the experiment (Figure 3d). EBA mice treated with FnAb
cream had significantly decreased TEWL compared with EBA
mice treated with IgG control cream, suggesting an improve-
ment in restoration of the epidermal/dermal barrier of the
wounds (Figure 3d). Histological examination of the blister
lesions of EBA mice treated with FnAb compared with IgG
control revealed a thinner epidermis similar to intact skin.
There was also decreased influx of polymorphic cells,
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Figure 1. Flightless I (Flii) is increased in response to blistering and can be modulated using topical Flii-neutralizing antibody (FnAb) cream. (a, b) Flii levels in
blister fluid (BF), acute wound fluid (AWF), and blister would fluid (BWF) collected from blisters (days 1–2 post induction) were analyzed using western blotting
and band densitometry. (c–h) Topical application of cream only, FnAb-DyLight cream, FnAb cream, or IgG control cream on intact porcine skin
showing FnAb-Dylight (green in d), Flii (green in e and f), and FnAb (red) localization and association (yellow). 406-Diamidino-2-phenylindole (blue).
Original magnification,  20. Insert, 100. Scale bar¼ 100mm. n¼ 3. e, epidermis; d, dermis; dotted line, dermal–epidermal junction. (i and j) Flii expression
in blistered skin (BS)-positive control, nontreated intact skin (skin), or intact skin of wild-type mice following a single FnAb cream application (D1–D3, days
post treatment) was analyzed using western blotting and band densitometry. BS, blistered skin; D, day. Albumin (Alb) and b-tubulin (b-tub) staining in a and g
show equal loading. The figure is representative of two independent experiments. Mean±SEM, *P40.05.
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significantly decreased histological blister scores, and
improved rate of healing (Figure 3e and f).
Treatment of mature blisters with FnAb cream improves healing
and restores the skin’s tensile strength
The timing of the application of the FnAb cream was
investigated by applying FnAb cream for three consecutive
days when the blisters were at their peak severity (day 12–14).
EBA mice treated with FnAb cream had lower numbers of
lesions and a lower percentage of skin blistering. In contrast,
EBA mice treated with IgG control cream had large numbers
of lesions and scabs covering existing blisters (Figure 4a
and b). The blisters of these mice treated with FnAb cream
at days 12–14 also had a faster restitution of the barrier
function and significantly decreased histological blister scores
compared with skin blistering observed in EBA mice treated
with IgG control cream (Figure 4c–e). To examine the
functional effect of FnAb on intact or blistered skin, skin strips
from wild-type mice and EBA mice treated with FnAb cream
or IgG control cream were assessed for their tensile skin
strength. Application of FnAb cream to intact skin of wild-type
mice resulted in an increased trend toward stronger skin;
however, this was not statistically significant. Induction of EB
significantly reduced the tensile strength of the skin; however,
treatment with FnAb cream led to significantly stronger, less
fragile skin (Figure 4f).
Repeated application of FnAb cream to skin during induction of
EBA before the onset of blistering reduces the extent of blistering
To determine whether FnAb cream could delay the onset
of skin blistering in an EBA mouse model, mouse skin
was treated with FnAb cream on alternate days over the first
10-day period during induction of EBA. Both EBA mice groups
treated with FnAb cream or IgG control cream developed skin
blistering; however, those treated with FnAb cream had
significantly fewer lesions, and the extent of skin blistering
was decreased at days 8–12 (Figure 5a–c). The FnAb cream–
treated EBA mice had decreased disruption of the skin barrier
function with lower TEWL values and significantly decreased
histological blister scores (Figure 5d and e). Repeated applica-
tion of FnAb cream to skin restored skin tensile strength with
significantly stronger blistered skin of EBA FnAb cream–treated
mice compared with blistered skin of EBA mice treated with
IgG control cream (Figure 5f).
Effect of FnAbs on dermal immunological responses of EBA mice
Application of xenogeneic antibodies, particularly when
applied in repeated doses, can induce changes in inflamma-
tory responses. To determine whether changes in immunolo-
gical reactions were produced in response to repeated
administration of FnAbs, the cellular infiltration of neutrophils
and macrophages was assessed. Blistered skin of mice
treated with FnAb or IgG control was assessed at day 12 or
day 16. Inflammatory cell infiltrate in blistered skin was
reduced at day 16 of the experiment compared with day 12;
however, no statistically significant difference was observed in
FnAb- or IgG-treated skin in either neutrophil or macrophage
cell numbers (Supplementary Figure S1 online).
DISCUSSION
Studies have shown that modulation of Flii activity by either
genetic knockdown or intradermal injection of FnAbs in both
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small and large animal models of wound healing and burn
injury improve the rate of healing and reduce early scar
formation (Cowin et al., 2007; Adams et al., 2009; Jackson
et al., 2012). Flii is also secreted in response to wounding,
suggesting a potential extracellular role for this actin-
remodeling protein (Cowin et al., 2007). To our knowledge
previously unreported, treatment of blistered skin with FnAb
cream reduces the severity and extent of blister formation in a
mouse model of EBA. FnAbs applied to intact or blistered skin
in a cream vehicle are absorbed into the epidermis and
papillary dermis, and can be detected in the skin for up to 3
days and can effectively reduce endogenous Flii protein
expression. The systemic effect of FnAb applied to the skin
was investigated, and while FnAbs were detected in the skin
locally for up to 3 days post application, they were not found
in serum or other organs, suggesting that the application of
FnAb cream to the skin remains localized to the skin.
Increased Flii levels contribute to impaired wound healing,
skin fragility, and increased dermal–epidermal separation
(Cowin et al., 2007; Kopecki et al., 2009, 2011a). The effect
of FnAb cream on the healing of blisters was investigated
using a murine model of EBA. In this model, mice develop
widespread blistering on their backs from day 8 of the
experiment, peaking at day 12, with healing occurring by
day 16 (Sitaru et al., 2005; Kopecki et al., 2011a). Initially,
mice backs were treated with topical FnAb cream during the
development of the blisters (day 8–10), with up to 50%
reduction in the extent of skin blistering being observed and
decrease in TEWL, suggesting an improvement in the protec-
tive skin barrier function. In agreement with previous studies
describing the positive effect of reduced Flii expression
(genetically or using FnAb) on cellular migration, proliferation,
and adhesion, as well as improved wound healing (Cowin
et al., 2007; Kopecki et al., 2009), EBA mice treated with
FnAb cream had a significantly decreased number of blister
lesions and lower histological blister scores. These findings are
in agreement with improved wound reepithelialization and
decreased blistering observed in Fliiþ / EBA mice (Kopecki
et al., 2011a) and improved healing observed in response to
intradermal injection of FnAb into porcine excisional wounds
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(Jackson et al., 2012). Indeed, wounds treated with FnAb show
an increased rate of reepithelialization and granulation tissue
formation associated with improved wound healing and
macroscopic appearance of early scars (Jackson et al.,
2012). Improved wound reepithelialization is vital for the
restoration of the skin barrier function.
Formation of a strong skin barrier contributes to skin
strength, whereas the quick recovery or reestablishment of
the skin barrier post blistering is critical for healing of blisters.
Application of FnAb cream to intact skin before blister
development (day 0–10) or to mature and healing blisters
(day 12–14) also decreased the severity and incidence of
skin blistering (up to 50%), with improved restoration of
the protective skin barrier. Interestingly, application of FnAb
cream to intact skin of wild-type mice resulted in an increas-
ing trend toward stronger skin and while this was not
significant it suggesting that reducing Flii levels when Flii is
not upregulated may also be beneficial for increasing skin
tensile strength. Of particular interest was the finding that the
application of FnAb cream significantly improved the skin
barrier function and reduced the skin fragility (up to 50%),
suggesting it might be able to reduce the fragility of EB skin
and help decrease the severity of blister formation observed in
these patients.
The uptake of oil-soluble agents is facilitated by the oil-
permeable nature of the skin. Previous studies using topical
administration of antibodies formulated in water-in-oil micro-
emulsion have shown the possibility of reducing inflammation
in mice skin (Himes et al., 2010). Despite our repeated topical
administration of a xenogeneic antibody to the skin, no
differences in neutrophil or macrophage cell infiltration were
observed. In addition, FnAbs were not detected in the serum
or in distal organs of the treated mice, suggesting that FnAbs
could be a potential treatment modality to be considered
for further development. Additional studies are still required to
investigate the toxicology, pharmacokinetics, and effective-
ness of FnAb cream before the commencement of any human
clinical trials with EB patients; however, the results presented
here suggest that FnAbs could potentially be used for the
treatment of blisters in EB. In addition, FnAb treatment could
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Figure 4. Flightless I-neutralizing antibody (FnAb) cream treatment of mature blisters improves healing and increases skin tensile strength. (a–c) Images of
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be used as a complementary approach to other treatment
modalities currently under investigation, including protein and
cell replacement therapies. Advantages of the development of
topical therapies for improved healing of blistered skin in
patients with EB include simple non-painful application during
dressing changes, with no viruses or living cells involved in
the delivery and local response to treatment. In conclusion,
Flii expression can be reduced using a repeated application of
FnAb cream, resulting in decreased blister severity, reduced
skin fragility, and improved skin barrier function.
MATERIALS AND METHODS
Antibodies
Mouse monoclonal anti-Flii antibody (sc-21716), rat monoclonal
neutrophil marker anti-NIMP-R14 (sc-59338), goat polyclonal macro-
phage marker anti-F4/80 (A-19) (sc-26642), and mouse monoclonal
anti-Albumin antibody (sc-51505) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Affinity-purified rabbit anti-
flightless (FnAb) raised against the L-rich repeat domain of flightless
protein was made by Mimotopes Pty (Clayton, Victoria, Australia) as
previously described (Adams et al., 2009). Murine IgG irrelevant anti-
body (I8765), b-tubulin antibody, and 406-diamidino-2-phenylindole
nucleic acid stain were obtained from Sigma (St Louis, MO).
Alexa-Fluor 488 goat anti-rabbit (A11008) and Alexa-Fluor 594 goat
anti-mouse (A11020) antibodies were obtained from Invitrogen
Australia Pty (Waverley, New South Wales, Australia).
Human samples
The clinical investigations were conducted under approval from SA
Department of Health Human Research Ethics Committee, in accor-
dance with the Declaration of Helsinski principles and with written
informed consent. Suction blisters were induced on the upper arms of
six healthy volunteers, with no known dermatological condition as
previously described (Koivukangas and Oikarinen, 2003). Briefly,
blisters were induced using a blister suction device (GlaxoSmithKline,
Melbourne, Victoria, Australia) tightened onto the forearm and con-
nected to the pump for 1 hour under a constant pressure of 90 kPa.
The suction results in the separation of the epidermis from the dermis
at the level of lamina lucida in the basement membrane, resulting in
blister cavity filled with tissue fluid consisting of interstitial fluid and
small portion of proteins from the serum. Blisters were lanced and
fluid was collected using an insulin syringe. Blister wounds were
dressed daily using Tegaderm transparent film dressings (3M, St Paul,
MN), and blister wound fluid was collected from the dressings at day
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Figure 5. Repeated application of flightless I-neutralizing antibody (FnAb) cream as a preventative measure reduces the severity of blister formation in
epidermolysis bullosa acquisita (EBA) mice. (a–c) Images of EBA mice blisters (day 12) treated with FnAb cream or IgG control cream over 10 alternate days
were analyzed for macroscopic blister wound area using Image Pro-Plus. (d) Graphical representation of transepidermal water loss (TEWL) in mice treated
with FnAb cream or IgG control cream. (e) Graphical representation of the histological blister score indicative of the rate of blister healing following
preventative application of topical FnAb cream or IgG control cream to mice skin. (f) Graphical representation of skin tensile strength following preventative
application of topical FnAb cream or IgG control cream to mice skin. n¼4. Mean±SEM, *P40.05.
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1 and day 2 post initial blister induction. Acute wound fluid control
was collected from patients attending the Wound Clinic, The Queen
Elisabeth Hospital, Adelaide. Protein from wound fluid samples was
precipitated using standard trichloroacetic acid methods as previously
described (Jiang et al., 2004), and western blotting was performed
following standard methods previously described (Kopecki et al.,
2009).
FnAb cream formulation
FnAb cream formulation was prepared by mixing the aqueous
hypoallergenic Sorbolene cream (cetomacrogel cream without gly-
cerol) with rabbit polyclonal FnAb (50mg ml 1). The Sorbolene
cream used in these experiments is the aqueous cream that is well
absorbed into the skin, contains no active ingredients, and is routinely
used for preparations of various dermatological treatments. The
concentration of FnAb used in these studies is same as the effective
dose determined in our previous in vivo studies. The FnAb cream
(200ml) was gently rubbed into the skin of mice, and volumes of FnAb
cream formulation used were enough to allow the majority of the
cream to be absorbed by the skin by the time the mice recovered from
anesthesia. No dressings were applied in this study. FnAb-DyLight
cream used in porcine ex vivo experiments was prepared in above
described method and concentrations, except FnAb antibody was
firstly conjugated to DyLight Fluor 488 following manufacturer’s
instructions, DyLight Fluor 488 Antibody Labeling Kit (53024)
(Thermo Scientific, Rockford, IL).
Animal studies
Intact skin from male Large White pigs was collected for ex vivo
experiments and immunohistochemistry following approval from the
University of Adelaide Ethics Committee and the IMVS Ethics
Committee following the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes. Briefly, intact porcine skin
was mounted on a sterile disk and pinned out using four sterile
25-gauge needles, taking care to preserve the natural tension of the
skin. Six explants (n¼ 3 pigs) were cultured in DMEM supplemented
with 10% FBS at the air–liquid interface, with the epidermis being
exposed to air and the dermis being submerged in medium. Hundred
microliter of cream only, FnAb-DyLight Fluor 488 cream (50mg ml 1
fluorescence-labeled FnAb-DyLight in aqueous cetomacrogol cream),
FnAb cream (50mg ml 1 FnAb in aqueous cetomacrogol cream), or
dose-matched IgG control cream was rubbed into the epidermis and
the explants were returned to the 37 1C 5%CO2 incubator and
incubated for 3 days. After this period, skin explants were collected,
formalin fixed, and paraffin embedded. Sections of the skin were
processed for immunohistochemical detection of Flii and FnAb.
All studies performed in mice were with wild-type mice of BALB/c
background. All experiments were approved by the Animal Ethics
Committees of the Adelaide Child, Youth, and Women’s Health
Service following the Australian Code of Practice for the Care and the
Use of Animals for Scientific Purposes. EBA was induced in 3–4-
week-old wild-type mice with rabbit anti-mouse ColVII antibody
injected subcutaneously as described previously (Kopecki et al.,
2011a). To facilitate easier identification of blisters and application
of FnAb cream, at the start of the experiments, mice back skin was
shaved and hair was removed using hair removal cream (Veet, Reckitt
Benckiser, West Ryde, New South Wales, Australia), followed by
washing with PBS to ensure no residual hair removal cream was
interfering with experiments. Mice back skin was treated with 200 ml
of FnAb cream (50mg ml 1 FnAb in aqueous cetomacrogol cream) by
gentle rubbing of the cream onto the skin (n¼ 4/time point). A dose-
matched irrelevant IgG control cream was also used on a separate
EBA cohort of mice (n¼ 4/time point). Treatment was on days 0–10
(alternative days), daily 8–10, or daily 12–14 (n¼ 4/time point/
treatment). Digital images of blistered skin were taken daily and
analyzed for macroscopic assessment of blistering using Image Pro
Plus, as previously described (Kopecki et al., 2011a). Measurements
of TEWL were obtained with a calibrated Vapometer evaporimeter
(Delfin Technologies, Kuopio, Finland) on days 0–10 or 7–16
following the manufacturer’s instructions. At day 12 or 16, mice
were killed using CO2 asphyxiation and cervical dislocation. Samples
of back skin were collected in 10% buffered formalin for histological
blister scoring as previously described (Kopecki et al., 2011a).
Additional samples of skin were collected for biochemical analysis
and snap-frozen in liquid nitrogen. Strips of skin were assessed using
tensiometry to determine skin strength using the Mecmesin Advanced
Force Gauge AFG-100N (Mecmesin, Slinfold, UK) with a motorized
test stand (Mecmesin M1000E, Mecmesin) at a speed of
3 cm minute 1 following the manufacturer’s instructions. Organs,
tissues, and serum of wild-type mice with no EB that were treated
with a single application of FnAb cream or IgG control cream were
collected for biochemical analysis and for the detection of Flii and
FnAbs.
Materials and methods for histology, immunohistochemistry,
western blotting, FnAb detection ELISA, and statistical analysis may
be found in supporting information, Supplementary materials and
methods.
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